论文信息 - Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial - 字舞流文

Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial

S. Murad | K. Goh | A. Kamarulzaman | A. Avihingsanon | W. Chan | T. Cressey | F. Simon | H. Tee | B. Pécoul | I. Andrieux-Meyer | M. Lallemant | Satawat Thongsawat | Nicolas Salvadori | S. Tan | S. Thanprasertsuk | S. Omar | S. Khemnark | J. Brenner | N. D. Silva | H. Omar | S. Siva | Sudhesh Kumar | M. Hassan | N. Asimah | H. Said | K. Thetket | J.-M. Piedagne